Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.
|Videos|December 13, 2018
Targeting PI3K Remains Complex in Cancer Therapy
Author(s)Lewis C. Cantley, PhD
Dr. Lewis Cantley discusses targeting the PI3K pathway in breast cancer and the importance of managing ambient insulin levels during therapy.
Advertisement
Dr. Lewis Cantley discusses targeting the PI3K pathway in breast cancer and the importance of managing ambient insulin levels during therapy.
Advertisement
Related to this article
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
3
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
4
Personalized Vaccines May Have Utility Across All Lung Cancer Stages
5